Clinical Pilot and Feasibility Award

Spring 2020
Letter of Intent (LOI) and Full Application

POLICIES AND GUIDELINES

Published: August 9, 2019
Letter of Intent Deadline: September 27, 2019
Full Application Deadline: February 10, 2020
I. ABOUT THE CYSTIC FIBROSIS FOUNDATION
The mission of the Cystic Fibrosis Foundation (CFF) is to cure cystic fibrosis (CF) and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.

To achieve this mission, various types of grants and awards are offered to support meritorious research in CF.

II. CF FOUNDATION RESOURCES
The Cystic Fibrosis Foundation supports the development of a number of helpful tools and resources to assist the research community in accelerating the progress toward new scientific knowledge of and new therapies for cystic fibrosis. For more information on Tools and Resources for the CFF research community, please visit: https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/

CFF Patient Registry Data
The CF Foundation Patient Registry collects information on the health status of people with cystic fibrosis who receive care in CF Foundation-accredited care centers and agree to participate in the Registry. This information is used to create CF care guidelines, assist care teams providing care to individuals with CF, and guide quality improvement initiatives at care centers. Researchers also use the Patient Registry to study CF treatments and outcomes and to design CF clinical trials.

The Cystic Fibrosis Foundation Patient Registry is an invaluable tool for researchers who are interested in conducting studies about people with CF in the United States. About 50,000 individuals have been followed in the Registry, and many have been included for over 20 years. In addition, we recently linked the CF Foundation Patient Registry with the Pediatric Health Information System (PHIS) database. Investigators at PHIS sites can request to use these linked data. Instructions on how to request CFFPR data for your research project is included in the application instructions below: CFF Patient Registry Data Request Application

CFF Biorepository
Cystic fibrosis biological samples are available to qualified researchers to help develop promising new studies that will support CF research and aid in drug development and drug discovery. Biorepository samples come in many different forms: blood, urine, stool, tissue, and other material. These samples are stored under appropriate conditions that ensure they are preserved for future analysis.

Since 2006, the Cystic Fibrosis Foundation has collected and stored samples from a variety of clinical trials. The CF Foundation has developed a database that combines information from these samples with data from CF clinical trials and the CF Foundation Patient Registry to create a unique and specific sample profile. Instructions on how to request CFF Biorepository samples for your research project is included in the application instructions below: https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/CFFT-Biorepository/
Community Voice
The CF Foundation is committed to ensuring that the CF community’s voice is heard in all of our activities. In December 2014, the CF Foundation created Community Voice, formerly known as the CF Adult and Family Advisors group, to serve as a consultative body and partner to the Foundation on various activities. Research Voice, a sub-committee within Community Voice, consists of people with CF and their family members who undergo special training on the basics of clinical research to provide insight and feedback to the research community.

Opportunities to partner with the community occur throughout the stages of a research project. Recently, several CFF funded investigator-initiated clinical research projects have utilized community engagement through Community Voice to successfully execute and complete their projects. The CF Foundation strongly encourages you to engage people with cystic fibrosis throughout the stages of clinical research. Based on your goals and objectives, the CF Foundation will work with you to determine which mechanisms are most appropriate. To learn more about how community insights can help you optimize your research project, email CommunityVoice@cff.org.

National Resource Centers
Specialized procedures are often needed to measure the outcomes of cystic fibrosis clinical trials. These include both laboratory-based measurements, such as cytology and inflammatory markers, and interpretive outcomes, such as computed tomography and nasal potential difference. NRCs provide centralized expertise in a variety of research outcome measures relevant to CF clinical research. For more information about National Resource Centers, please visit: https://www.cff.org/Research/Researcher-Resources/Therapeutics-Development-Network/Working-with-the-TDN/National-Resource-Centers/

III. INVESTIGATOR-INITIATED CLINICAL RESEARCH PROGRAMS OVERVIEW
Program Description
The Foundation’s Investigator-initiated Clinical Research Programs aim to provide support for academic clinical research projects that have the potential to make an important contribution to the CF Foundation’s mission. Academic clinical research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical (observational or interventional), translational or epidemiologic study approaches.

The CF Foundation funds investigator-initiated clinical research through the Clinical Pilot and Feasibility (CP&FA), Clinical Research Award (CRA), and the Clinical Research Award Plus (CRA+), and other various targeted funding opportunities that occur throughout the year.

Funding for any investigator-initiated clinical research award is a two-tier process. The CF Foundation requires CP&FA, CRA, and CRA+ to submit either a Letter of Intent (LOI) or Concept Proposal in advance of a full application. Full applications are accepted on an invite-only basis; however, applicants may be able to by-pass the LOI with prior approval from the Program Officer.
In 2018, the CF Foundation received 79 LOIs for the CP&FA and CRA. The Foundation invited 40 investigators to submit full applications. Of those received, the Foundation funded 10 CP&FA and 9 CRAs. The breakdown for 2018 funding is shown below.

<table>
<thead>
<tr>
<th></th>
<th>Clinical Pilot &amp; Feasibility Award</th>
<th>Clinical Research Award</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Spring 2018</td>
<td>Fall 2018</td>
</tr>
<tr>
<td>LOIs Received</td>
<td>17</td>
<td>22</td>
</tr>
<tr>
<td>Full Applications Received</td>
<td>9</td>
<td>14</td>
</tr>
<tr>
<td>Funded</td>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>

Table 1: Number of LOIs and full applications received and funded for the 2018 Spring and Fall C-P&FA and CRA cycles.

Areas of Interest
- The CF Foundation seeks applications for the Clinical Research Award from all areas of clinical research that will have an impact on the lives of people with CF. However, the following research areas are of particular interest to the CF Foundation as they will address critical needs of people with CF:
  - Studies that investigate CF disease complications (lung, GI tract, liver, pancreas, reproduction, mental health, endocrine etc.)
  - Strategies to improve care and quality of life of people with CF
  - Assessment and validation of biomarkers, clinical trial tools, outcome measures and efficacy endpoints
  - Translational or clinical studies in lung transplant\(^1\) research
  - Characterization of CF disease manifestations and management in the era of highly effective modulator therapy
  - Novel interventions that improve CF patient care and outcomes
  - Studies designed to translate laboratory findings of disease pathogenesis/treatment to clinical evaluation

Areas of Encouragement
In addition to CF Foundation Areas of Interest, extensive survey input from the CF community (people with CF, family members and caregivers) have identified key research Areas of Encouragement that are most important to them. The areas selected by the CF community are listed below in order of prioritization. Applications may address any topic area advancing CF care, treatment, or research. However, applications addressing the following areas in CF are particularly encouraged:
- Respiratory Microorganism Detection and Treatment
- Gastrointestinal symptoms (including, but not limited to, GERD, DIOS, and Pancreatitis)
- Reducing Treatment Burden
- CF-related Diabetes

---
\(^1\) In 2017, the CF Foundation created the Lung Transplant Initiative to address the unmet needs of people living with cystic fibrosis with advanced lung disease. The mission of this initiative is to improve the care and long-term outcomes of individuals with CF and advanced lung disease. For more information about this initiative, or the CF Foundation’s research priorities in lung transplant research, please email Al Faro (afaro@cff.org).
• Diet and Nutrition
• Mental Health
• CF-related Liver Disease (including cirrhosis and non-cirrhosis, gall stones, hepatic steatosis, and other clinical manifestations of portal hypertension)
• Exercise
• Sinus Disease
• Allergies and Asthma
• Alternative/Holistic Treatments and Therapies
• Sexual Reproductive Health
• Bone/Joint Heath
• Pain Management

IV. CLINICAL PILOT AND FEASIBILITY AWARD OVERVIEW

Clinical Pilot and Feasibility Awards are offered to support projects involving human subjects (see 45 CFR§46.102(f)) that will develop and test new hypotheses and/or new methods (or those being applied to the problems of cystic fibrosis for the first time), and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. The intent of these awards is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger-scale research and/or multi-center, collaborative trial. Special consideration will be given to those projects that pursue new approaches, study under-researched topics, or investigate more creative avenues of research to address the problems of CF. Applications for continued funding of existing projects, or for long-term support of an investigator, will not be considered.

General Guidelines:
• Applicants may request funding of up to $80,000 per year, plus an additional twelve (12) percent indirect costs.
• Awards may be approved for up to a two (2) year period. Funding for Year 2 is contingent upon submission and approval of a renewal progress report and the availability of funds.
• International applicants and institutions are required to submit additional information in accordance with U.S. regulations (see section VII.7.M in these guidelines).
• Preliminary data is not required; however, applicants must provide sufficient background information and rationale to support moving this work into human subjects research.
• Applying for support of these projects requires a two-step process. An applicant must first submit a Letter of Intent (LOI) by the announced deadline, and if approved, s/he may proceed to the full application. If not approved, a revised LOI may be resubmitted in the next LOI round, provided the applicant addresses, point-by-point, the questions raised by the reviewers.

Eligibility:
• United States residents and applicants from outside the United States are welcome to apply.
• Applicants must be independent investigators. An independent investigator is an individual who is out of fellowship training and whose institution allows them to submit applications for research funding as a Principle Investigator.
• Applicants must hold faculty level positions. Fellows may submit applications; however, funding will only be considered if they will hold a faculty-level appointment at the time of the award.
• Applicants must be a M.D., D.O., Ph.D., or dual M.D./D.O., Ph.D. scientist
• Industry-sponsored research projects are not eligible to apply through this program and instead should consider applying to the Therapeutics Development Awards program. For additional information, please contact grants@cff.org.

Budget Guidelines:
Direct costs may be requested for:
• Salary and Benefits
• Research supplies
• Equipment
• Research-related subject costs
• Consultant costs
• Support for multidisciplinary collaborations, including travel
• Travel costs for scientific/technical meeting(s)

Direct costs for the following are unallowable:
• Tuition

Indirect Costs up to twelve (12) percent may be requested from CFF. Indirect costs may be requested for all expenses except for the following:
• Equipment (items over US$5,000 in value)
• Computer software
• Software licenses

Applicants may request indirect costs on the first $25,000 of each subcontract for the project period.

V. REVIEW AND AWARD
Applications to the Clinical Pilot and Feasibility Award program are reviewed by the Clinical Research Committee (CRC), community representative reviewers, and the CFF.

Applications undergo scientific peer-review by the CRC and receive scores based on innovation, scientific merit, and impact on the CF Foundation’s mission. Applications will also be evaluated on their experimental design and methods, rationale, and statistical analysis methodology. Applicants should adequately describe how the hypothesis will be tested, demonstrate adequate power for testing the hypothesis, and clearly define all variables in their statistical analysis section. Applicants are required to consult with a biostatistician prior to submitting their proposals. In addition, applicants are required to include a biostatistician with a minimum of 5% effort on their project.

Community representative reviewers evaluate applications based on study design and feasibility from the perspective of people with CF. They also evaluate the project on its relevance to the CF
Foundation’s mission and the project’s potential to impact those living with CF. Community representative reviewers do not review an application for scientific merit. Reviews from the community representative reviewers are used to inform funding decisions.

Funding of awards is approved by the CFF Board of Directors and is based on the availability of funds, priority score assigned to each application, and recommendations of the CRC, community representative reviewers, and CFF Program Officers. All awards are subject to compliance with applicable regulations and CFF policies.

**Chief reasons for assigning low priority scores to applications during review include the following:**
- Insufficient information or documentation
- Inadequate statement of hypothesis, experimental design or methods
- Failure of the applicant to describe potential relevance of the proposed study to issues in CF
- Failure of the applicant to document the necessary skills or training to accomplish the goals of the proposal
- Failure of the applicant to meet all the criteria described in these guidelines
- Failure of the applicant to demonstrate adequate level of statistical support and appropriate plan for data analysis

*CFF may withdraw applications receiving low scores, and/or those deemed nonresponsive to the program announcement, before the CRC review meeting. In these cases, CFF will notify applicants if their application has been withdrawn without discussion. Applications that have not been discussed in two review meetings will not be accepted for further consideration by CFF. Applicants must address reviewer critiques in order to resubmit their applications during future application cycles.*

**VI. SUBMISSION INFORMATION & GENERAL TIMELINE**

A Letter of Intent (LOI) must be submitted and approved prior to submitting a full application.

Submit online at proposalCENTRAL: [https://proposalcentral.com/](https://proposalcentral.com/)
(Refer to Sections VI and VII of these guidelines for specific submission instructions.)

Investigators with a previously approved LOI who did not submit a full application, and/or investigators submitting a revised application may request to bypass the LOI stage. These requests must be e-mailed to grants@cff.org with “Clinical P&F LOI Bypass Request” in the subject line. LOI bypasses are granted on a case-by-case basis and the CFF Grants and Contracts Office will send a notification of the final determination.

Applicants whose **LOI was not approved in an earlier submission** may resubmit the LOI with (1) appropriate revisions, and (2) an attachment that provides a point-by-point response to the limitations noted by the reviewers.
General Timeline:

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOI Submission Deadline</td>
<td>September 27, 2019</td>
</tr>
<tr>
<td>LOI Applicant Notified</td>
<td>early-December 2019</td>
</tr>
<tr>
<td>Full Application Deadline</td>
<td>February 10, 2020</td>
</tr>
<tr>
<td>Review by Clinical Research Committee</td>
<td>mid-April 2020</td>
</tr>
<tr>
<td>Notification to Applicants</td>
<td>mid-May 2020</td>
</tr>
<tr>
<td>Earliest Start Date for Awarded Projects</td>
<td>July 1, 2020</td>
</tr>
</tbody>
</table>

VII. LETTER OF INTENT SUBMISSION GUIDELINES

LOI Submission Deadline: Friday, September 27, 2019 at 5:00 PM (EST)

LOI must be submitted online at proposalCENTRAL: https://proposalcentral.com/

The LOI will be considered incomplete if it fails to comply with these instructions, or if the submitted material is insufficient to permit adequate review. CFF reviews LOIs electronically, and only documents submitted online at proposalCENTRAL will be reviewed.

Documents should be typed using:
- Times New Roman 12 or Arial 11
- Margins: No less than a half inch on each side

Login at proposalCENTRAL: https://proposalcentral.com/

First-time applicants must register to create a username and password for proposalCENTRAL and will need to complete a profile online before applying. If you are already registered and cannot remember your password, click on the “Forgot Your Username/Password?” link below the “Application Login” fields. Note: Use the Customer Service link on the top right of each screen as needed.

Grant and award opportunities, including this program, are listed on the opening screen, but you must be logged in to see them.

Select the gray tab labeled “Grant Opportunities” found in the upper right-hand side of the page.

Click on the light blue “Filter by Grant Maker” button to the left and scroll down to locate Cystic Fibrosis Foundation Therapeutics in the list.

Locate the listing for the “Clinical Pilot and Feasibility Award with LOI” program. Click on the “Apply Now” button in the column on the far right to open the application.

Applicants may stop at any point but must click the “Save” button before exiting in order to save their work. When logging in to continue, click on the blue tab, “Proposals”, and then the “Edit” button.
The following sections are listed in the navigation menu to the left of the application screen. Click on each section and follow the directions.

1. **Title Page:** Enter the title of your project and indicate whether this is a new LOI or a resubmission of an earlier version.

2. **Download Templates & Instructions:** Download the available templates applicable to the project, fill them out and upload them when completed in Section #8. Templates available include:
   - LOI Cover Sheet
   - Biographical Sketch(es) of Key Personnel
   - Response to Prior LOI Critique (if resubmission)
   - LOI Project Description

3. **Enable Other User to Access this Proposal:** Complete this section online if you wish to designate access to another individual, such as an assistant who has registered on proposalCENTRAL. Enter the email address of the individual and in the “Permissions” column, use the pulldown menu to select the type of access you wish to give. Please note that only delegates who are granted “Administrator” rights can submit applications on behalf of the applicant. Check the “Auto Notify” box and then “Save”.

4. **Applicant/PI:** If a profile was completed upon registration, the fields in this section will already be populated with the information entered in your Professional Profile. If you need to make any changes, click the “Edit Professional Profile” button and follow the instructions. If a profile was not completed, enter the information in the required fields and click “Save”.

5. **Institution:** If a profile was completed upon registration, the Principal Investigator’s (PI) institution will be preloaded as Lead Institution. If a profile was not completed, enter the required information and click “Save”. Be sure to use the full legal name of the institution.

6. **Abstracts/Relevance/Keywords:** In the space provided online for abstracts, provide a statement of no more than 2,000 characters (including spaces) explaining the subject of the research proposal and its relationship to CF. Two different abstracts are required as follows:
   - **Lay Abstract:** statement will be used to inform the non-scientific departments of the CFF and the general public of the nature of this work. Applicants should not include any confidential or proprietary information, including intellectual property, in the lay abstract.
   - **Scientific Abstract:** This statement will be used to inform the scientific community.
   - **Summary of Relevance to CFF mission**
     All applications are reviewed and scored not only on scientific merit but also on relevance to CFF’s mission.

   *The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full,*
productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.

Provide a statement of no more than 3,000 characters (including spaces) summarizing the relevance of the proposed research to the health and well-being of CF patients, for a non-scientific audience who may or may not have a background in the subspecialty of the proposed research. If applicable, describe how your project addresses one or more of the Areas of Encouragement identified by the CF community (see Section III of these guidelines). Describe how you will engage the CF Community in your research.

- **Keywords**: From the lists of options provided in this section, select all applicable research type, research topics, and keywords for the proposed project. A minimum of one (1) option must be selected per category. Click each keyword you want to select, then the Add (+) icon, until you have all applicable keywords selected on the list to the right.

7. **Budget Summary**: Fill in the start date and end date and applicable amounts for each year of support requested by completing the online fields (Period 1, 2). A separate budget must be completed for each year of funding requested. All Clinical Pilot and Feasibility awards are for a maximum of two years, and up to $80,000 per year (plus an additional 12% indirect costs).

8. **Attachments**: Complete the templates downloaded from Section #2 and upload them here as PDF documents. Below are instructions specific to each template.

A. **LOI Cover Sheet (template available for download)**

The Principal Investigator and any Co-Investigators (if applicable) are required to sign where indicated. (The Applicant Institution’s Authorized Institutional Official’s signature is not required for the LOI).

Complete all fields within the Cover Sheet and be sure to select YES or NO for the two questions regarding access to the CFF Patient Registry and CFF Biorepository Specimens. If selecting YES for access to either, please see Section E. below.

The completed LOI Cover Sheet must be uploaded with the submission.

B. **Biographical Sketch(es) of Key Personnel (NIH template available for download)**

CFF defines “key project personnel” as any individual with an advanced degree who will play an instrumental role in the research project. An NIH Biographical Sketch form should be completed for each key project personnel and uploaded as PDF. The maximum length for each biosketch is five (5) pages. Personnel must include a biostatistician with a minimum of 5% effort during the entire project period.
C. **Response to Prior LOI Critique (template available for download, if applicable)**
   Resubmissions of LOI applications that were previously not approved are required to make a point-by-point response to the limitations noted in the critique of the earlier submission.

D. **LOI Project Description (template available for download)**
   Upload a PDF copy of the completed document. Maximum of three (3) pages (not including the literature cited). Components should include:
   - **Statement of Hypothesis and Specific Aims**: State concisely and realistically the intent of the proposed research and the hypothesis to be tested. The specific aims should be relevant to the mission of the Cystic Fibrosis Foundation.
   - **Innovation Statement**: Provide a brief statement that highlights how the proposed study is innovative in study concept, research methods or technology, or adaptations of existing methods or technologies for a non-science audience.
   - **Brief Study Design**: Describe the study design, including a statistical section which focuses on the precision of estimates that will be used to design future studies.
   - **Literature Cited**: References should be numbered in the sequence that they appear in the text. Each citation must include the names of authors, the name of the journal or book, volume number, page number and year of publication (titles are optional).

E. **CFF Biorepository Clinical Specimen Confirmation Letter (if applicable)**
   Since 2006, the Cystic Fibrosis Foundation has collected and stored samples from a variety of clinical trials. The CF Foundation has developed a database that combines information from these samples with data from CF clinical trials and the CF Foundation Patient Registry to create a unique and specific sample profile. To request clinical samples to use in the proposed study, download and complete the template from [https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/CFFT-Biorepository/](https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/CFFT-Biorepository/). Applicants must supply a letter from the clinical research program manager confirming samples are available for their use with their LOI submission. For more information, contact Linh Do, CF Foundation clinical research program manager, at ldo@cff.org or 301-841-2648.

   **Note**: If applicable, funding is contingent upon approval and availability to access clinical specimens.

9. **Validate**: Upon completing your LOI, click on the “Validate” button on the main screen. Attend to any omissions/errors as prompted onscreen, and then click “Validate” again.

10. **Print Face Pages**: Face Pages are not required for an LOI. Continue to Section #11.

11. **Submit**: Click on the gray button with blue lettering. CFF will not receive your application unless the submit button is clicked.

   **Confirmation**: Applicants will receive an e-mail confirmation from proposalCENTRAL (not from CFF) that the LOI was successfully submitted. This e-mail will be your only
VIII. FULL APPLICATION GUIDELINES

Full Application Deadline: Monday, February 10, 2020 at 5:00 PM (EST)

Applications must be submitted online at proposalCENTRAL: https://proposalcentral.com/

Applications received without an approved LOI will not be reviewed.

An application will be considered incomplete if it fails to comply with the instructions, or if the submitted material is insufficient to permit adequate review. CFF reviews applications electronically, and only documents submitted online at proposalCENTRAL will be reviewed.

Documents should be typed using:
• Font: Times New Roman 12 or Arial 11
• Margins: No less than a half inch on each side

Note: When all the documents have been uploaded to proposalCENTRAL, the system will compile them into a single PDF file in the correct sequence as shown in Section VIII. ELECTRONIC APPLICATION CHECKLIST.

Log-in at proposalCENTRAL: https://proposalcentral.com/

First-time applicants must register to create a username and password for proposalCENTRAL and will need to complete a profile online before applying. If you are already registered and cannot remember your password, click on the “Forgot Your Username/Password?” link below the “Application Login” fields. Note: Use the Customer Service link on the top right of each screen as needed.

Grant and award opportunities, including this program, are listed on the opening screen, but you must be logged in to see them.

Select the gray tab labeled “Grant Opportunities” found in the upper right-hand side of the page.

Click on the light blue “Filter by Grant Maker” button to the left and scroll down to locate Cystic Fibrosis Foundation in the list.

Locate the listing for the “Clinical Pilot and Feasibility Award with LOI” program. Click on the “Apply Now” button in the column on the far right to open the application form.
Applicants may stop at any point but must click the “Save” button before exiting in order to save their work. When logging in to continue, click on the blue tab, “Proposals,” and then the “Edit” button.

The following sections are listed in the navigation menu to the left of the application screen. Click on each section and follow the directions.

1. **Title Page:** Enter the title of your project and indicate whether this is a resubmission of an application that was reviewed earlier. In addition, please indicate YES/NO if you will be requesting access to the Patient Registry Data or Biorepository Clinical Specimens as outlined in Section #10. K. and L. respectively.

2. **Download Templates & Instructions:** Download the available templates applicable to the project, fill them out and upload them when completed in Section #10. Templates available include:
   - Instructions for Requesting Letters of Reference
   - Research Plan
   - Protocol Synopsis
   - Critique Response (if resubmission)
   - Budget Detail
   - Budget Justification
   - Biographical Sketches of Key Personnel
   - Other Support
   - Facilities Available
   - Results of Past and Current CFF/CFFT Support
   - Names and Addresses of References for Junior Investigators
   - Data Safety Monitoring Plan
   - **CFF Patient Registry Data Request Application**
   - International Institution Form (if applicable)
   - Appendices

3. **Enable Other User to Access this Proposal:** Complete this section online if you wish to designate access to another individual, such as an assistant who has registered on proposalCENTRAL. Enter the email address of the individual and in the “Permissions” column, use the pulldown menu to select the type of access you wish to give. Please note that only delegates who are granted “Administrator” rights can submit applications on behalf of the applicant. Check the “Auto Notify” box and then “Save”.

4. **Applicant/PI:** If a profile was completed upon registration, the fields in this section will already be populated with the information entered in your Professional Profile. If you need to make any changes, click the “Edit Professional Profile” button and follow the instructions. If a profile was not completed, enter the required information and click “Save”.

5. **Institution & Contacts:** If a profile was completed upon registration, the Principal Investigator’s (PI) institution will be preloaded as Lead Institution. If a profile was not completed, enter the required information and click “Save”. Be sure to use the full legal name of the institution.
6. **Letters of Reference for Junior Investigators**: CFF defines “junior investigator” as any individual who has not received a CFF/CFFT Research Grant or NIH equivalent (e.g. R01, R21, R23) as a Principal Investigator OR is within their first five years of their first academic appointment at the level of Assistant Professor or equivalent. Letters of Reference for junior investigators must be submitted by the following individuals:

- **The Chair of the applicant’s department at the applicant Institution** – The letter of reference from the Department Chair should indicate the release of sufficient space and facilities for the work described, as well as guarantee the time commitment of the investigator to the project. If the applicant is currently a fellow, the letter of reference should include confirmation of the pending faculty-level appointment.
- **At least two other individuals** familiar with the applicant’s scientific interests and abilities.

Enter the email addresses of the individuals who will be asked to submit Letters of Reference for the applicant. Automated emails (with instructions) will be sent to each Referee through the proposalCENTRAL website. *The letters must be uploaded by the referees prior to submitting the application, preferably one (1) week before the application deadline.* Additionally, applicants must complete the “Names and Addresses of References for Junior Investigators” template and upload it in Section #10.

**Note:** Detailed Instructions on how to invite referees to submit the letters of reference are also available in a downloadable document found in Section #2. Letters uploaded to proposalCENTRAL should not be password protected or otherwise encrypted. Such encryption will cause errors in assembling a single-print PDF of the application. *The applicant should inform the individuals writing letters to not include password protection on their documents.*

*Senior investigators, or those who have received a prior CFF/CFFT Research Grant or NIH equivalent, are not required to submit Letters of Reference; however, if they are new to CF research, Letters of Support and/or Collaboration should be provided and uploaded as Appendices (in Section #10).*

7. **Abstracts/Relevance/Keywords**: In the space provided online for abstracts, provide a statement of no more than 2,000 characters (including spaces) explaining the subject of the research proposal and its relationship to CF. Two different abstracts are required as follows:

- **Lay Abstract:** This statement will be used to inform the non-scientific departments of CFF and the general public of the nature of this work. Applicants should not include any confidential or proprietary information, including intellectual property, in the lay abstract.
- **Scientific Abstract:** This statement will be used to inform the scientific community.
- **Summary of Relevance to CFF mission**
  All applications are reviewed and scored not only for scientific merit, innovation and impact but also for relevance to CFF’s mission.
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.

Provide a statement of no more than 3,000 characters (including spaces) summarizing the relevance of the proposed research to the health and well-being of CF patients, for a non-scientific audience who may or may not have a background in the subspecialty of the proposed research. If applicable, describe how your project addresses one or more of the Areas of Encouragement identified by the CF community (see Section III of these guidelines). Describe how you will engage the CF Community in your research.

• Keywords: From the lists of options provided in this section, select all applicable research type, research topics, and keywords for the proposed project. A minimum of one (1) option must be selected per category. Click each keyword you want to select, then the Add (+) icon, until you have all applicable keywords selected on the list to the right.

8. Budget Summary: Fill in the start and end date and applicable amounts for each year of support requested by completing the online fields (Period 1, 2). A separate budget must be completed for each year of funding requested. All Clinical Pilot and Feasibility awards are for a maximum of two years, and up to $80,000/year (plus an additional 12% indirect costs). Note: The Budget Detail template and Budget Justification template downloaded in Section #2 must be completed and uploaded in Section #10.

9. Organization Assurances: Select the type of assurances that are applicable to the project and provide all required information (i.e. IRB, IACUC, and/or IBC/rDNA approval letters) and status at the time of submitting your application. Refer to Section M. ORGANIZATION ASSURANCES & CERTIFICATIONS in these guidelines for details.

10. Research Plan & Supporting Documents: In this section, upload the completed templates downloaded in Section #2 above. Fill out the fields describing the attachment, select the attachment type from the pulldown menu, choose the file to be uploaded, and click the “Upload Attachment” button to upload the file. Do this for each attachment.

Below are instructions specific to each template as well as additional information regarding other application components.

A. Research Plan (template available for download)
• Key figures and legends must be included in the Research Plan. If uploaded as Appendices, they will NOT be reviewed.
• At the top of each page, type the PI's name. Each page must be sequentially numbered at the bottom.
• Research Plans are limited to seven (7) single-sided pages, not including the Literature Cited. Applications exceeding this page limit will not be reviewed. Include
sufficient information to permit effective review without reference to previous applications. Information should be presented in a clear and concise manner, while being specific and informative.

- If the application is a resubmission of an earlier application, revisions should be clearly indicated by a change in font, or bolded or underlined. CFF will not review resubmissions that have not been revised. Beginning in 2018, applicant’s will only be allowed to revise and resubmit their full application for a specific project one time unless granted permission from the CFF Program Officer.

a. **Hypothesis and Specific Aims:** State concisely and realistically the intent of the proposed research and the hypothesis to be tested. The specific aims should be relevant to the mission of the Cystic Fibrosis Foundation. Do not exceed one page.

b. **Innovation Statement:** Provide a brief statement that highlights how the proposed study is innovative in study concept, research methods or technology, or adaptations of existing methods or technologies for a non-science audience.

c. **Background and Significance:** Briefly describe the background. Critically evaluate existing knowledge and specifically identify the gaps that the project is intended to fill. Concisely state the importance and rationale of this research by relating the specific aims to longer-term objectives. This section should also show the potential importance of the proposed work to CF.

d. **Preliminary Results:** If applicable, provide a detailed discussion of any preliminary results.

e. **Experimental Design and Methods:** Provide a detailed discussion of the experimental design and methods to be used to accomplish the specific aims. Please discuss: study hypothesis; primary and secondary outcome measures; study sample-inclusion and exclusion criteria; sample size estimates*; subject enrollment including age range; pubertal status (if applicable); sex distribution; randomization scheme (if applicable); description of experimental procedures and schedule including a study time-line; drugs and dosage; measures of compliance; follow-up schedule including a study time-line for full project up to two years; efficacy and safety evaluation, data monitoring and quality control; and a description of your proposed data analysis and statistical procedures for your hypothesis testing. Make every attempt to be concise and succinct.

*For sample size estimates, please provide all estimates of means, standard deviations, rates or proportions used to calculate each of your sample size or power estimates. Please include in the statistical section whether you will use a one or two-tailed test, the power selected for such a test (if making a sample size calculation), and the reference for your sample size or power calculation. In instances of pilot studies where some of these parameters are unknown, we will accept your best estimates of the unknown parameters if preliminary data are not available, and if your calculation is a preliminary estimate before formal sample size can be calculated for a larger study. Please identify if you are making estimates from data or from personal estimates. This section must document access to adequate numbers of subjects.

f. **Limitations and Potential Pitfalls:** Discuss potential difficulties and/or limitations of the proposed procedures and alternative approaches to achieve aims. Point out any
procedures, situations or materials that may be hazardous to personnel or patients and the precautions to be exercised.

**g. Consultant Arrangements:** If the proposed project includes consultant arrangements and/or collaboration with other individuals outside the applicant’s group, describe the working relationships and support this description by letter(s) of intent signed by collaborating individual(s). If clinical material required by this award is to be furnished by other individuals, include a statement from these individuals agreeing to their participation and precautions taken to ensure anonymity of patients.

**h. Literature Cited:** References should be numbered in the sequence that they appear in the text and listed at the end of the Research Plan. Each citation must include the names of authors, the name of the journal or book, volume number, page number and year of publication (titles are optional).

**B. Protocol Synopsis (template available for download, if applicable)**
Complete the information required in the available template for each aspect of the study protocol.

**C. Critique Response (template available for download)**
For new applications: Provide a point-by-point response to the limitations noted in the critiques of the LOI, using the template provided.

For resubmissions: Provide a point-by-point response to the prior reviews.

There is no page limit to your responses, but please be concise and succinct. Beginning in 2018, applicant’s will only be allowed to revise and resubmit their full application for a specific project **one time** unless granted permission from the CFF Program Officer.

**D. Budget Detail and Budget Justification (separate templates available for download)**
Fill out a separate Budget Detail and Budget Justification template for each year of support requested. In the space provided on each page, indicate the year or period as well as start and end dates for the proposed budget period. Up to two (2) years of funding may be requested. (Be sure the Budget Detail matches the online budget summary in Section #8).

**Budget Guidelines**
- Applicants are required to include a biostatistician with a minimum of 5% effort on their project.
- Services that are part of routine medical care (as defined by the U.S. Department of Health and Human Services) may not be included in the project budget. Whenever possible, the price of services (e.g., X-rays, EKGs, PFTs, etc.) provided by the institution should be negotiated to the lowest possible non-profit price.
- Separate professional fees for interpretation of data (e.g., from X-rays, lab tests, PFTs) may not be included when such interpretation is performed by the named investigator(s), co-investigator(s), or consultants as part of the project, other than in exceptional circumstances. In such cases, justification for these fees must be described in detail in the budget justification template.
• Under most circumstances, hospitalization costs of study subjects cannot be included in this budget.

• **Budget Detail – Direct Costs**
  
  **Salary & Benefits** – List the names and positions of all professional and non-professional personnel involved in the project, whether or not salaries are requested. Indicate the percent effort on the project for all personnel. For each individual, be sure to complete all fields on the Budget Detail in full on the template provided. In accordance with National Institutes of Health (NIH) policy, salary requests may not use an institutional base salary in excess of the current federal salary cap of $192,300; when calculating salary requests, the NIH cap must be adhered to. Fringe benefits may be requested if they are treated consistently by the applicant institution as a direct cost to all funding agencies and foundations.

  **Consultant Costs** – Give the name and institutional affiliation of any consultant who has agreed to serve in this capacity, including statisticians and physicians in connection with the project if they are not listed under personnel. In the budget justification, briefly describe services to be performed, the number of days, rate of compensation, per diem and any other associated costs.

  **Subcontractors** – Detailed budgets for each subcontract, including indirect costs, must be provided for each year of support (complete and upload a Budget Detail and Budget Justification template for each subcontract). For applications that include a subcontract with a third party, the applicant may request indirect costs on the first $25,000 of each subcontract per project period. Negotiations of subcontracts are between the applicant institution and the subcontractor.

  **Major Equipment** – List all items of equipment greater than $5,000 requested and the cost of each item. If funds are requested to purchase equipment that is equivalent to items listed under “Facilities Available,” justify the duplication. Justify any item of equipment for which the need may not be obvious.

  **Travel** – Describe the purpose of any CF-relevant travel. Please note: expenses for travel outside the North American continent for domestic applicants, including travel to Hawaii, Puerto Rico, and other U.S. territories are not allowable expenses without prior written approval from the CFF Grants and Contracts Office. Travel expenses may not exceed **$1,500 per person, per year**. Additional travel expenses may be requested and will be considered on a case-by-case basis. Registration fees associated with conferences should be listed under “Other Expenses.”

  **Patient Research Costs** – Funds may be requested for patient research costs specifically related to the proposed research. The basis for estimating funds requested in this category must be justified and applicants must provide detailed information regarding the proposed costs (e.g., number of procedures, cost per procedure, ancillary costs). The scientific need for patient research costs will be
considered in the review. Negotiation of these costs are between the applicant institution and the service provider.

If approved as part of the application, patient research costs are capped at the amount requested in the budget and under no circumstances is CFF responsible for any costs that are later determined non-covered by third party insurers. Applicants and applicant institutions acknowledge that CFF is solely a provider of funding for the research performed under an approved award and not a sponsor of the research as defined by the FDA (21 CFR §312.3(b)).

Consumable Supplies – Itemize supplies e.g. disposables, reagents, chemicals, animals, in separate categories and give the estimated cost of each category. If animals are involved, state the number, unit purchase cost, and unit care cost.

Other Expenses – Itemize other expenses by major categories, such as subcontracts, duplication costs, publication costs, conference registration fees, computer charges, and other research costs (e.g., recruitment flyers, brochures, patient travel cost reimbursement, and reasonable patient stipends for participation), etc. Justify all items.

- **Budget Detail – Indirect Costs**
  Indirect costs of up to twelve (12) percent may be requested from CFF. Indirect costs may be requested for all expenses except for the following:
  o Major equipment (items over $5,000 in value)
  o Computer software
  o Software licenses

  Applicants may request indirect costs on the first $25,000 of each subcontract for the project period.

- **Budget Justification**
  Describe costs listed in the Budget Detail. Use major categories, such as Personnel, Consultant Costs, Equipment, etc.

E. **Biographical Sketches of Key Personnel (template available for download)**
  Complete and upload an NIH Biographical Sketch for all key project personnel, beginning with the Principal Investigator. (CFF defines “key project personnel” as any individual with an advanced degree that will play an instrumental role in the accomplishment of the research project.) Do not exceed five (5) pages per person.

F. **Other Support (template available for download)**
  Complete and upload an “Other Support” form, for all key project personnel, beginning with the Principal Investigator. There is no page limitation.
G. Facilities Available (template available for download)
Describe the facilities and equipment available at the applicant’s institution that will be used for this project, such as laboratory, clinical, animal, computer, office, etc. Provide any additional information about the environment, including any support services available that will be utilized. Describe their pertinent capabilities, proximity and anticipated extent of use. If facilities or equipment at a consultant’s or collaborative site will be used, they should be identified and clearly described. There is no page limit. Use continuation pages, if necessary.

H. Results of Past and Current CFF/CFFT Support (template available for download)
Identify the results of past and current CFF/CFFT support (e.g., subsequent funding from other sources, journal articles, and invited presentations) and the CFF/CFFT award from which they resulted for the past five years. Please note that the following information must be included with each research project identified:
- CFF/CFFT Award #
- Principal Investigator (PI)
- CFF/CFFT Project Title
- Applicant’s Title on Project
- Project Start/End Dates
- Total CFF/CFFT Award Amount
- Results of Support

I. Names and Addresses of References for Junior Investigators (template available for download)
List the names, titles, and contact information of the individuals who have been asked to submit Letters of Reference on the applicant’s behalf. A PDF copy of the completed form should be uploaded. Though not required to submit Letters of Reference, Senior investigators should still check the box in the template that identifies them as Senior investigators and upload the form to proposalCENTRAL.

J. Data Safety Monitoring Plan (template available for download, upload if applicable)
In compliance with Federal regulations, all applicants must submit a general description of the Data Safety Monitoring Plan (DSMP) for any proposed study that places human subjects at more than minimal risk. A DSMP helps to ensure subject safety, as well the validity and integrity of the data. Furthermore, a DSMP allows for the monitoring of study data to assess whether or not an early termination is necessary for safety or efficacy reasons.

The extent of monitoring required for a study is dependent on the level of risk involved for the subjects, as well as the size and complexity of the study. Large, multi-center CFF-funded interventional clinical trials may be required to utilize a Data Safety and Monitoring Board (DSMB). In addition, CFF may require that investigators utilize the CFF DSMB for any other interventional CF clinical trial that meets one or more of the following criteria:
- Multi-center;
• Randomized;
• Conducted in an emergency setting;
• Use high-risk interventions, such as gene therapy, gene transfer, or bronchoscopy; or
  Include particularly vulnerable study populations, such as pediatric patients.

**Note:** On the available template, please check whether a DSMP is required and upload the template regardless of the response.

**Address the following areas in the DSMP:**

**Assessment of Risk** – Describe the level of risk the proposed research presents to subject participants and provide a detailed justification for the level of risk. Discuss who will monitor the study.

**Level of Risk**
- **Minimal Risk**
  - Study poses no more risk than expected in daily life (blood draw, physical exam, etc.)
  - Observational studies
  - Survey or questionnaire studies
- **Low Risk**
  - Post-marketing study Phase IV drug or device, as defined by FDA
- **Moderate Risk**
  - Substantial risk (>5%) of a Serious Adverse Event (SAE) originating from the underlying condition of the enrolled subject
  - Phase I or II study with available safety data in humans
- **High Risk**
  - Involves an intervention or invasive procedure with substantial risk
  - Involves the use of a new chemical or drug for which there is little or no toxicology data in humans
  - A gene therapy study or research involving recombinant DNA or RNA molecules (gene transfer)
  - Involves vulnerable populations (pediatric, pregnant, etc.)

**Anticipated Adverse Events and Grading Scale** – Describe anticipated adverse events (AEs), including expected frequency and the grading scale to be used. Discuss plans for addressing AEs.

**Reporting of AEs** – Detail the plan for reporting AEs, including who shall be notified in the event an AE should occur.

**Safety Monitoring Plan** – Describe all tests, evaluations, and exclusion criteria that will be implemented to ensure and monitor the safety of human subjects. Discuss stopping rules for the study subjects or for the overall study if necessary.
Safety Reviews – Describe the process for monitoring and reviewing subject safety data, including the frequency of such reviews. Include details as to who will perform the monitoring and plans for reporting. If utilizing the CFF DSMB, provide the frequency of meetings, the reporting requirements, including AEs and SAEs, and the procedure for interim reporting as necessary. If this information is not available at the time of submission of the application, note that CFF will not release awarded payments until it is provided.

Registrations for Investigator-Initiated Clinical Trials:
- Clinicaltrials.gov (United States): Applicants are required to register all non-exempt human subject studies in the ClinicalTrials.gov database to ensure information is freely available on CFF-funded trials within the community. The registration should be no later than twenty-one (21) days after the first subject is enrolled. CFF requires copies of documentation confirming this registration, when applicable.
- EudraCT Registration (European Union): For interventional clinical trials with medicinal products conducted in the European Union, the Institution must provide documentation to CFF confirming registration of the clinical trial when applicable.

K. CFF Patient Registry Data Request (download available, upload if applicable)
Researchers who wish to request Registry data for their proposed clinical research study must complete and submit the “Application for CFFPR Data and Confidentiality Agreement” application to datarequests@cff.org prior to submitting their full application to CFF. The formal application for CFF Patient Registry Data Requests can be found at https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/Patient-Registry-Data-Requests/

Note: The application must be submitted using the online system available from the link above and the email from the system indicating receipt of the application must be uploaded to the submission. Funding is contingent upon approval to access registry data.

L. CFF Biorepository Clinical Specimen Confirmation Letter (if applicable)
Since 2006, the Cystic Fibrosis Foundation has collected and stored samples from a variety of clinical trials. The CF Foundation has developed a database that combines information from these samples with data from CF clinical trials and the CF Foundation Patient Registry to create a unique and specific sample profile. To request clinical samples to use in the proposed study, download and complete the template from https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/CFFT-Biorepository/. Applicants must supply a letter from the clinical research program manager confirming samples are available for their use with their LOI submission. For more information, contact Linh Do, CF Foundation clinical research program manager, at ldo@cff.org or 301-841-2648.
Note: Applicants must upload the confirmation letter provided by the CFF Clinical Research Program Manager to the application. Funding is contingent upon approval and availability to access clinical specimens.

M. Organization Assurances & Certifications

Research Involving Human Subjects: CFF policy pertaining to the protection of individuals as research subjects requires that for each proposal awarded, the applicant institution certify in writing that an Institutional Review Board (IRB) has reviewed and approved the procedures for the use of human subjects, or human organs, tissues and body fluids, in the proposed research, in accordance with Department of Health and Human Services policies found at https://www.hhs.gov/ohrp/regulations-and-policy/index.html. IRB status must be indicated on the “Organization Assurances” section of the application in proposalCENTRAL. CFF will not release awarded funds until this certification of IRB approval is received and on file with the Grants and Contracts Office. This certification of IRB approval, if available at the time of application, should be included as an appendix to the application.

Research Involving Recombinant or Synthetic Nucleic Acid Molecules: All research involving recombinant or synthetic nucleic acid and human gene transfer studies supported by CFF must meet the requirements contained in the document NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (updated April 2019). This publication and announcements of modifications and changes to the NIH Guidelines are available from the Office of Science and Policy, National Institutes of Health, 6705 Rockledge Drive, Ste 750, MSC 7985, Bethesda, MD, 20892-7985 or online at https://osp.od.nih.gov/biotechnology/nih-guidelines/

The purpose of the NIH Guidelines is to specify practices for the construction and handling of: (i) recombinant nucleic acid molecules; (ii) synthetic nucleic acid molecules, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, or (iii) cells, organisms, and viruses containing such molecules.

CFF policy pertaining to recombinant and synthetic nucleic acid research requires that the applicant institution certify in writing that an IBC has reviewed and approved the procedures involving recombinant and synthetic nucleic acids in accordance with the NIH Guidelines. IBC status must be indicated on the “Organization Assurances” section of the application in proposalCENTRAL. The Grants and Contracts Office will not release awarded funds until this certification of IBC approval is received and on file. This certification of IBC approval, if available at the time of application, should be included as an appendix to the application.

Research Involving Animals: Award applications submitted to CFF involving the use of animals must meet the guidelines of the National Institutes of Health found at https://grants.nih.gov/grants/olaw/olaw.htm, which require that all proposed studies be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC). In addition, CFF awardee institutions and laboratories must be accredited by the American
Association for Accreditation of Laboratory Animal Care (AAALAC) and/or have other verifiable assurances that the institution and laboratory meet appropriate standards. IACUC status must be indicated on the “Organization Assurances” section of the application in proposalCENTRAL. The Grants and Contracts Office will not release awarded funds until this certification of IACUC approval is received and on file. This certification of IACUC approval, if available at the time of application, should be included as an appendix to the application.

N. International Institution Form (template available for download, if applicable)
Applicants whose institution is not a United States based entity must complete the International Institution Form. Upload a PDF version of the completed and signed form, together with the following documents*:

- A copy of the institution’s most recent Mission Statement.
- A copy of the institution’s Tax Exemption Letter, if institution is nonprofit.
- A description of other sources of support, such as official awards, private endowments, and commercial activities, received by the institution.
- A copy of the institution’s Standard Operating Procedure(s) or relevant policy to ensure that funds provided are neither distributed to terrorists or their support networks, nor are funds used for activities that support terrorism or terrorist organizations. If your institution does not have a relevant policy, please provide a statement signed by an institutional official indicating that award funds will not be used to support terrorism or terrorist organizations.
- For-profit institutions must submit a complete list of key employees, members of the governing board, and/or other senior management.

*Applicants must provide English translations for all non-English documents, including material provided in support of the Research Plan.

O. Appendices (upload materials as PDF documents)
Appendices are restricted to the following three (3) categories*:

- Signed Letters of Support and/or Collaboration: A Letter of Collaboration from Co-PIs, if any, should be uploaded and included in the application. Investigators new to CF research are required to consult/collaborate with an established CF investigator/clinician either at their own institution or another. The letter from the collaborator/consultant should be explicit as to how the proposed work is relevant to CF and how he/she will assist the investigator new to CF research. 
  Note: Junior investigators must provide such letters by contacting referees via section #6 of the navigation bar.

- Certification of IRB approval, or other applicable organization assurances documents such as IACUC and IBC Approval Letters, if available at the time of application.

- Up to three (3) reprints of the applicant’s work relating to the general area of research in the proposal may be uploaded in PDF format.

*No other types of Appendices will be reviewed.
11. **PI Data Sheet:** Fill in the required fields, save and exit.

12. **Print Face Pages:** Follow the prompts on the screen to generate and print a Face Page. The Face Page will be populated automatically with data entered in the online application (applicant’s name, institution, title of application, etc.). The Face Page must be signed by the Principal Investigator and Authorized Institutional Official and uploaded in Section #10. Co-Principal Investigators, if any, are not expected to sign the Face Page.

13. **Validate:** Upon completing your application, click on the “**Validate**” button on the main screen. Attend to any omissions/errors as prompted onscreen, and then click “**Validate**” again.

14. **Submit:** Click on the gray button with blue lettering. **Submit** CFF will not receive your application until and unless the “**Submit**” button is clicked.

**Confirmation:** Applicants will receive an e-mail confirmation from proposalCENTRAL (not from CFF) that the application was successfully submitted. This e-mail will be your only acknowledgement. If you do not receive this confirmation, please contact proposalCENTRAL immediately to ensure that your submission was submitted and processed.

```
For technical support with the online application:

proposalCENTRAL at pcsupport@altum.com or
800-875-2562 on weekdays, 8:00 a.m. to 5:00 p.m. (Eastern)

For program/content information:

CFF Grants and Contracts at grants@cff.org or 301-841-2614
```
IX. ELECTRONIC APPLICATION CHECKLIST

LOI Submission Deadline: Friday, September 27, 2019 at 5:00 PM (EST)
Full Application Deadline: Monday, February 10, 2020 at 5:00 PM (EST)

Applications must be submitted online at proposalCENTRAL: https://proposalcentral.com/

LETTER OF INTENT
☐ Signed Cover Sheet - (upload)
☐ Biographical Sketch(es) of Key Personnel - (upload)
☐ Response to Prior LOI Critique (if resubmission) – (upload)
☐ LOI Project Description - (upload)
☐ CFF Biorepository Clinical Specimen Request Confirmation letter (if applicable)

FULL APPLICATION
Face Page (upload) which includes:
☐ Signatures
  ☐ Principal Investigator (Co-PI’s are not required to sign)
  ☐ The Official authorized to sign on behalf of the Applicant Institution
☐ Applicant/PI information - (online)
☐ Complete Institution and PI Contact information, including correct mailing address - (online)
☐ Organization Assurances (check those that apply online)
  ☐ Human Subjects Certification - Minimal patient risk only
  ☐ Research Involving recombinant or synthetic nucleic acid molecules information
  ☐ Research Involving Animals information

Research Plan, Supporting Documents and Appendix:
☐ Abstracts ~ Summary of Relevance ~ Keywords - (complete online)
☐ Research Plan - (upload)
  ☐ Hypothesis and Specific Aims
  ☐ Innovation Statement
  ☐ Background and Significance
  ☐ Preliminary Results
  ☐ Experimental Design and Methods
  ☐ Limitations and Potential Pitfalls
  ☐ Consultants/Collaborative Arrangements
  ☐ Literature Cited (not included in Research Plan page limitation)
☐ Protocol Synopsis – (upload)
☐ Critique Response (if resubmission) - (upload, if applicable)
☐ Budget Detail for each year and for each subcontract, when applicable - (upload)
☐ Budget Justification for each year and for each subcontract, when applicable - (upload)
☐ Biographical Sketches of Key Personnel - (upload)
☐ Other Support for all key personnel (NIH Format) - (upload)
☐ Facilities Available - (upload)
☐ Results of Past and Current CFF/CFFT Support - (upload)
☐ Letters of Reference for Junior Investigators - (invite referees to submit via proposalCENTRAL
  – Note: applicant will not be able to see the letters)
☐ Names and Addresses of References for Junior Investigators - (upload)
☐ Data Safety Monitoring Plan – (upload, if applicable)
☐ CFF Biorepository Clinical Specimen Request Confirmation letter – (upload, if applicable)
☐ CFF Patient Registry Data
   ☐ Application for CFFPR Data and Confidentiality Agreement – (upload, if applicable)
☐ Verification of Applicant Institution’s Tax Status - (upload)
   ☐ W-9 (U.S. applicants) or W-8BEN-E (non-U.S. applicants)
   ☐ 501(c)3, IRS Form 147C or equivalent tax status letter
☐ International Institution Form (non-U.S. based entities only) - (upload, if applicable)
   ☐ Institution’s most recent Mission Statement
   ☐ Institution’s Tax Exemption Letter, if institution is not-for-profit
   ☐ Description of other sources of support
   ☐ Institution’s Standard Operating Procedure(s) or relevant policy to ensure that funds provided are neither distributed to terrorists or their support networks nor used for activities that support terrorism or terrorist organizations
   ☐ For-profit institutions must submit a complete list of key employees, members of the governing board, and/or other senior management
☐ Appendices - (upload as PDF documents, if applicable)
   ☐ Signed Letter(s) of Support and/or Collaboration
   ☐ Certification of IRB approval, or other applicable organization assurances documents such as IACUC and IBC Approval Letters, if available at the time of application
   ☐ Up to three (3) reprints of the applicant’s work relating to the general area of research in the proposal